Dublin, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027" report to their offering.

Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, hepatitis C causes no noticeable symptoms until the liver has been significantly damaged. Symptoms are often vague such as flu-like muscle aches and fatigue.

This report provides the current prevalent population for Chronic Hepatitis C across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, Russia, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Chronic Hepatitis C have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Chronic hepatitis C is most often associated with co-infections with other chronic viral infections including:

- HIV Co-infection
- HBV Co-infection
- HCV co-infection

Likely downstream events associated with chronic HCV infection include:

- Cirrhosis of the liver
- Hepatocellular carcinoma
- Excess mortality associated with liver disease / decompensated liver function

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for Chronic Hepatitis C

10. Genotype of HCV infection in Chronic Hepatitis C patients
10.1 Predominant Genotype

11. Main route of infection for Chronic HCV patients

12. Major viral co-infection in Chronic HCV patients

13. Access to healthcare for CHCV patients

14. Events and outcomes for CHCV patients

15. Abbreviations used in the report

16. Patient-Based Offering

17. Online Pricing Data and Platforms

18. References

19. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/qfbs47/chronic_hepatitis

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Infectious Diseases Drugs, Liver and Kidney Disorders Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.